The short version of alpha-MSH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-26. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
== Structure == The gene encoding LepA is known to be the first cistron as part of a bicistron operon. LepA is a polypeptide of 599 amino acids with a molecular weight of 67 kDa. The amino acid sequence of LepA indicates that it is a G protein, which consists of five known domains. The first four domains are strongly related to domains I, II, III, and V of primary elongation factor EF-G. However, the last domain of LepA is unique. This specific domain resides on the C-terminal end of the protein structure. This arrangement of LepA has been observed in the mitochondria of yeast cells to human cells.
=== Approved drugs === Emoxypine (ethylmethylhydroxypyridine; Mexidol) – antioxidant and unknown mechanism of action [135] Tandospirone (metanopirone; Sediel; SM-3997) – serotonin 5-HT1A receptor partial agonist [136] Tianeptine (Coaxil; Stablon; Tatinol) – weak atypical μ-opioid receptor agonist and other actions [137]
=== Pharmacokinetics === Difloxacin is rapidly and almost completely absorbed after oral administration, and approximately 50% is bound to circulating plasma proteins. It is metabolized primarily by the liver through glucuronidation and secreted in the bile. It can also be reabsorbed with the bile. This allows reentry into the blood stream and recirculation, a mechanism that can extend the half-life. The longer half-life allows for once daily dosing. In contrast to other fluoroquinolones, renal clearance accounts for only 5% of the removal of difloxacin from the canine system, which makes it an attractive choice for dogs with compromised renal function.
Sources: en.wikipedia.org
John Arnold Cranston (working with Frederick Soddy and Ada Hitchins) is also credited with discovering the most stable isotope in 1915, but he delayed his announcement due to being called for service in the First World War. The longest-lived and most abundant (nearly 100%) naturally occurring isotope of protactinium, 231Pa, has a half-life of 32,760 years and occurs in the decay chain of uranium-235. Much smaller trace amounts of the short-lived 234Pa and its nuclear isomer 234mPa occur in the decay chain of uranium-238. 233Pa occurs as a result of the decay of thorium-233 as part of the chain of events necessary to produce uranium-233 by neutron irradiation of 232Th. It is an undesired intermediate product in thorium-based nuclear reactors, and is therefore removed from the active zone of the reactor during the breeding process. Ocean science uses the element to understand the ancient ocean's geography: analysis of the relative concentrations of various uranium, thorium, and protactinium isotopes in water and minerals is used in radiometric dating of sediments up to 175,000 years old, and in modeling of various geological processes. Protactinium is unusual among non-primordial elements in that its natural isotopic composition is extremely uniform across typical terrestrial samples, because essentially all naturally occurring protactinium is 231Pa, produced solely along a single pathway (namely, from the decay of primordial 235U).
Zopiclone is used for the short-term treatment of insomnia where difficulty with sleep initiation or sleep maintenance are prominent symptoms. Long-term use is not recommended, as tolerance, dependence, and addiction can occur. Benzodiazepine-like drugs decrease sleep latency by 10 to 20 minutes. However, no benzodiazepine-like drug has shown clinically significant increase in total sleep time which is defined as at least 30 minutes. Tolerance develops within days to weeks. The risk of developing tolerance with benzodiazepine-like drugs is comparable to benzodiazepines. Zopiclone is recommended to be taken at the lowest effective dose, with a duration of 2–3 weeks for short-term insomnia. Use of zopiclone more than 4 weeks is not recommended. Caution must be taken when the compound is used in conjunction with benzodiazepines, sedatives or other drugs affecting the central nervous system. One low-quality study found that zopiclone is ineffective in improving sleep quality or increasing sleep time in shift workers. Cognitive behavioral therapy has been found to be superior to zopiclone in the treatment of insomnia and has been found to have lasting effects on sleep quality for at least a year after therapy.
He worked as a music journalist and ran a magazine publishing business, launching Flexipop magazine in 1980 with ex-Record Mirror journalist Barry Cain. Robin Lustig (born 30 August 1948, London); was foreign correspondent in Madrid for Reuters; worked for The Observer as editor and Middle East correspondent; also presented The World Tonight, Newsstand, Stop Press, and File on 4 for Radio 4, and Newshour on the BBC World Service; presented programme covering sudden death of Diana, Princess of Wales, hours after announcement was made; also presented Talking Point (later renamed Have Your Say) for BBC World Service, BBC World TV; guests included Nelson Mandela, Thabo Mbeki, Olusegun Obasanjo, Hugo Chávez and Tony Blair; later worked on The World Tonight and Newshour; for BBC World Service, has presented every UK election night programme since 1997 as well as United States presidential election programmes; reported on elections in Iran, Israel, Japan, Russia and Zimbabwe; presented The World Tonight from Afghanistan, China, Iran, Iraq, Japan, Kosovo and Mexico; was awarded Gold Medal at the New York Radio Festival and broadcast live from Moscow on last day of Soviet Union; in 1998, won Sony Silver Award; was described in The Times as "arguably the best news presenter anywhere in radio after John Humphrys"; received Charles Wheeler award for outstanding contribution to broadcast journalism.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.